Comparative Pharmacology
Head-to-head clinical analysis: IVRA versus RUFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IVRA versus RUFEN.
IVRA vs RUFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ivermectin binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased chloride ion influx and hyperpolarization, resulting in paralysis and death of the parasite. It also interacts with gamma-aminobutyric acid (GABA)-gated chloride channels.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, decreasing prostaglandin synthesis.
Intravenous 500 mg every 6 hours.
400-800 mg orally three to four times daily; maximum 3200 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 12-15 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours) and in elderly patients.
Terminal elimination half-life is 2-4 hours; clinical context: short half-life requires frequent dosing for sustained analgesia.
Renal excretion of unchanged drug accounts for approximately 10-20% of elimination; fecal/biliary excretion is the primary route (60-70% as metabolites, primarily unchanged drug via bile).
Primarily renal (approximately 90% as glucuronide conjugates and unchanged drug), with minor biliary/fecal elimination (<10%).
Category C
Category C
Nonsteroidal Anti-Inflammatory Drug (NSAID)
Nonsteroidal Anti-Inflammatory Drug (NSAID)